Norcliffe Capital are pleased to announce the completion of a £6 million fundraise for Biosceptre International.
Biosceptre International are developing groundbreaking CAR T cancer therapeutics with a unique target that is only found on cancer cells, not normal cells, that should mitigate the usual side effects associated with cancer treatments. Biosceptre is such an exciting project for us to support. They have a world class team, an expansive patent portfolio and incredible results to date.
Personally, this project had huge significance. In the same week we launched Biosceptre I received devastating news. Both my father and stepmother were diagnosed with cancer.
It felt surreal that we had launched a cancer therapeutic investment at the same time I was told my stepmother had bowel cancer and my father was terminal with metastasised prostate cancer. It made the fundraise into the development of cancer treatments even more important.
The support from our investors has been astounding, especially during such a difficult year for all, and we want to thank you for your support.